

K160829 illumigene Mycoplasma Direct DNA Amplification Assay, illumigene Mycoplasma Direct External Controls, illumipro-10Jun 13, 2016
80 days to decisionK160829 · Product code: **OZX** · Microbiology
Source: <https://www.510kdatabase.net/k160829/>**SUBMISSION DETAILS**

| | |
|-----------------------|--|
| Decision | Substantially Equivalent (Cleared) |
| Submission type | Traditional |
| Device classification | Mycoplasma Pneumoniae Dna Assay System (OZX) |
| Date received | Mar 25, 2016 |
| Decision date | Jun 13, 2016 |
| Days to decision | 80 days |
| Third-party review | No |
| Summary / Statement | Summary |

APPLICANT

| | |
|----------------|---|
| Company | Meridian Bioscience, Inc. |
| Location | Cincinnati, OH, US |
| Contact | MICHELLE L. SMITH |
| Website | https://www.meridianbioscience.com |
| 510(k) history | 38 submissions · 37 cleared · 2003-2025 |

Meridian Bioscience, Inc. is a diagnostic and life science solutions company with a manufacturing facility in Cincinnati, US. The company develops integrated diagnostic products and molecular reagents for clinical and research applications. Meridian has received FDA 510(k) clearances from total submissions since 2003. The company specializes exclusively in Microbiology devices, including molecular detection assays, pathogen identification systems, and diagnostic analyzers. The latest clearance in 2025 reflects continued regulatory activity and product innovation. Recent c...